Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
New multiple sclerosis phenotypic classification.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Arzerra
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Novel MS Drug Offers Good Functional Outcomes
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
The Inaugural Hillel Panitch, MD Multiple Sclerosis Symposium
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Genzyme’s Lemtrada Approved by the FDA
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis

Pages